Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Hormone Receptor Positive Breast Cancer Clear all
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
BGB-21447, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Iowa City, Iowa • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dexamethasone based mouthwash, Everolimus, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Fayetteville, Arkansas • Anaheim, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
non-interventional
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
301
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 224 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Placebo, Palbociclib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
lapatinib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Abemaciclib, Fulvestrant, Aromatase Inhibitors
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Interventions
GVV858, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions
Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
32
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, computed tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced May 21, 2026, 11:11 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
Interventions
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
LEE011, BYL719, fulvestrant, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions
NKT3964
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Bevacizumab, Anastrozole, Fulvestrant
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
11
States / cities
Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
Interventions
TRX518, Cyclophosphamide, Avelumab
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions
Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
therapeutic estradiol, exemestane, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Biological · Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced May 21, 2026, 11:11 PM EDT